• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Merck Announces FDA Approval of Ebola Zaire Vaccine Ervebo


Treatment indicated for patients aged 12 months and older.

Microscopic view of the ebola virus illustration. Image Credit: Adobe Stock Images/Monika Wisniewska

Image Credit: Adobe Stock Images/Monika Wisniewska

Merck has revealed the FDA approval of an expanded indication for Ervebo, for the prevention of disease caused by Zaire ebolavirus for individuals aged one year and older. Initially, the vaccine had been approved for patients aged 18 and older. The treatment does not support other ebolavirus variants and the current duration of protection is unknown.

“Ebola virus disease is contagious and potentially deadly in both children and adults. We’re proud of the approval of ERVEBO for the prevention of disease caused by Zaire ebolavirus in children as young as 12 months old, which is another milestone in our continued commitment to help address the global health threat caused by Zaire ebolavirus,” said Eliav Barr, SVP, head of global clinical development and chief medical officer, Merck Research Laboratories, in a company press release.

Reference: U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older. Merck. August 3, 2023. Accessed August 8, 2023. https://www.merck.com/news/u-s-fda-approves-mercks-ervebo-ebola-zaire-vaccine-live-for-use-in-children-12-months-of-age-and-older/

Related Videos